EUVIMEDEUVIMED entdecken
Kommentar

TRKing down drug resistance in NTRK fusion‐positive cancers †

Abigail G Parrish iD, Frank Szulzewsky iD

The Journal of Pathology · 2024

DOI: 10.1002/path.6341 ↗

Kurz gefasst

Kommentar in der Zeitschrift The Journal of Pathology, 2024. Verfasst von Abigail G Parrish und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a recent issue of The Journal of Pathology , Chen and colleagues established novel patient‐derived ex vivo models of NTRK fusion‐positive soft tissue sarcoma to characterize resistance mechanisms against targeted therapy with tyrosine kinase inhibitors. Prolonged exposure to escalating concentrations of the tyrosine kinase inhibitor, entrectinib, ultimately led to the occurrence of resistant clones that harbored an inactivating mutation in the NF2 gene, not previously described in this context, accompanied by increased PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling. Finally, an inhibitor screen identified, among others, MEK and mTOR inhibitors as potential combination agents. © 2024 The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmProtein Kinase InhibitorsHumansNeurofibromin 2Oncogene Proteins, FusionBenzamidesReceptor, trkASignal TransductionIndazolesMutationSarcomaAntineoplastic AgentsTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

NF2patient‐derived ex vivo cell modeltherapy resistancetyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsNeurofibromin 2Oncogene Proteins, FusionentrectinibNF2 protein, humanBenzamidesReceptor, trkAIndazolesAntineoplastic AgentsTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.

ORCID-Profile: Abigail G Parrish, Frank Szulzewsky

Zitieren

APA

Parrish, A. G., & Szulzewsky, F. (2024). TRKing down drug resistance in NTRK fusion‐positive cancers †. The Journal of Pathology. https://doi.org/10.1002/path.6341

Vancouver

Parrish AG, Szulzewsky F. TRKing down drug resistance in NTRK fusion‐positive cancers †. The Journal of Pathology. 2024. doi:10.1002/path.6341

BibTeX
@article{Parrish2024,
  author = {Parrish, Abigail G and Szulzewsky, Frank},
  title = {TRKing down drug resistance in NTRK fusion‐positive cancers †},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6341}
}
Kostenlos starten →